scholarly journals OUTCOMES AFTER IMPLANTATION OF BARE-METAL, COVERED AND DRUG-ELUTING STENTS FOR THE TREATMENT OF PULMONARY VEIN STENOSIS IN CHILDREN

2011 ◽  
Vol 57 (14) ◽  
pp. E2007
Author(s):  
Sowmya Balasubramanian ◽  
Audrey C. Marshall ◽  
Lynn F. Peng ◽  
James E. Lock ◽  
Doff B. McElhinney
2019 ◽  
Vol 29 (8) ◽  
pp. 1057-1065 ◽  
Author(s):  
Yoshihiko Kurita ◽  
Kenji Baba ◽  
Maiko Kondo ◽  
Takahiro Eitoku ◽  
Shingo Kasahara ◽  
...  

AbstractBackground:Pulmonary vein stenosis (PVS) is a condition with challenging treatment and leads to severe cardiac failure and pulmonary hypertension. Despite aggressive surgical or catheter-based intervention, the prognosis of PVS is unsatisfactory. This study aimed to assess the prognosis and to establish appropriate treatment strategies.Methods:We retrospectively reviewed endovascular treatments for PVS (2001–2017) from the clinical database at the Okayama University Hospital.Results:A total of 24 patients underwent PVS associated with total anomalous pulmonary venous connection and 7 patients underwent isolated congenital PVS. In total, 53 stenotic pulmonary veins were subjected to endovascular treatments; 40 of them were stented by hybrid (29) and percutaneous procedures (11) (bare-metal stent, n = 34; drug-eluting stent, n = 9). Stent size of hybrid stenting was larger than percutaneous stenting. Median follow-up duration from the onset of PVS was 24 months (4–134 months). Survival rate was 71 and 49% at 1 and 5 years, respectively. There was no statistically significant difference between stent placement and survival; however, patients who underwent bare-metal stent implantation had statistically better survival than those who underwent drug-eluting stent implantation or balloon angioplasty. Early onset of stenosis, timing of stenting, and small vessel diameter of pulmonary vein before stenting were considered as risk factors for in-stent restenosis. Freedom from re-intervention was 50 and 26% at 1 and 2 years.Conclusions:To improve survival and stent patency, implantation of large stent is important. However, re-intervention after stenting is also significant to obtain good outcome.


EP Europace ◽  
2010 ◽  
Vol 13 (1) ◽  
pp. 57-61 ◽  
Author(s):  
T. J. R. De Potter ◽  
B. Schmidt ◽  
K. R. J. Chun ◽  
C. Schneider ◽  
R. Malisius ◽  
...  

EP Europace ◽  
2017 ◽  
Vol 20 (10) ◽  
pp. e148-e155 ◽  
Author(s):  
Thomas Fink ◽  
Michael Schlüter ◽  
Christian-Hendrik Heeger ◽  
Christine Lemes ◽  
Tina Lin ◽  
...  

2019 ◽  
Vol 29 (4) ◽  
pp. 541-543 ◽  
Author(s):  
Kuan-Chi Lai ◽  
Julie A. Brothers ◽  
Jason Z. Stoller

AbstractWe report a case of severe hypertriglyceridemia associated with an everolimus drug-eluting stent in an infant with pulmonary vein stenosis. We review from current literature the mechanisms by which everolimus may cause dyslipidaemia, pharmacokinetics of everolimus in drug-eluting stents, and treatments of hypertriglyceridemia. This case demonstrates the need to closely monitor serum triglyceride levels after everolimus drug-eluting stent placement in infants.


2017 ◽  
Vol 13 (1) ◽  
pp. 124-130 ◽  
Author(s):  
Jason F. Goldberg ◽  
Craig L. Jensen ◽  
Rajesh Krishnamurthy ◽  
Nidhy P. Varghese ◽  
Henri Justino

Sign in / Sign up

Export Citation Format

Share Document